Buy & Sell AbCellera Biologics Inc (ABCL) – AbCellera Biologics Inc Price Today
Aura AI Summary
Key Stats
- $1.66BMarket Cap
- HealthSector
- -22.86%3M Drawdown
- $1.29BEnterprise Value
- -Dividend Yield
- 93% Buy | 7% SellTrading Activity
- 39 daysTypical Hold Time
AbCellera Biologics Inc (ABCL) is currently valued at a market capitalization of $1.66B, with an enterprise value of $1.29B. Over the past 52 weeks, AbCellera Biologics Inc has traded between a low of $2.51 and a high of $6.46, highlighting its annual price range. Over the past three months, AbCellera Biologics Inc has recorded a drawdown of -22.86%, reflecting recent price volatility. On average, investors hold AbCellera Biologics Inc for approximately 39 days, indicating typical investor behavior on the platform.
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Most Recent News
Over 29 pharma firms advance 35+ Treg cell therapies, promising new treatments for autoimmune and transplant diseases.
The Treg cell-based therapies pipeline is robust with more than 29 pharmaceutical companies developing over 35 therapies targeting autoimmune diseases, graft-versus-host disease, and transplant rejection. Key players like Orca Bio, Cellenkos, and Que...

Tech stocks plunge as chip ETF SOXL drops 16%, AMD falls 6% amid fading recovery and SpaceX IPO jitters
Technology stocks saw a sharp decline after an initial morning rally faded, with the semiconductor-focused ETF SOXL plunging 16.43% and AMD dropping nearly 7%. The selloff was driven by active short selling and investor caution ahead of the upcoming ...

ERShares protects investors in XOVR ETF ahead of SpaceX's historic $75B IPO.
ERShares has implemented measures to protect long-term investors in its XOVR ETF, which holds private exposure to SpaceX, ahead of SpaceX's expected historic IPO on June 12. The fund will restrict large creation orders and may impose up to 2% redempt...
